New ulcerative colitis drug shows promise in early trial
Disease control
Terminated
This early-stage study tested a single injection of BB-TL1A-VIAL-HLE in 16 people—first in healthy adults and then in those with moderate-to-severe ulcerative colitis. The main goal was to check safety and see if the drug could improve colon inflammation. The trial was stopped ea…
Phase: PHASE1 • Sponsor: Vial Australia Pty Ltd • Aim: Disease control
Last updated May 01, 2026 16:00 UTC